Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PDS Biotechnology Corporation (PDSB)
NASDAQ:PDSB
Holding PDSB?
Track your performance easily
PDSB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.30 - $6.68
Previous CloseN/A
Volume197.50K
Average Volume (3M)319.55K
Market Cap
$57.98M
Enterprise Value$115.52M
Total Cash (Recent Filing)$106.40M
Total Debt (Recent Filing)$14.95M
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Mar 27, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding37,409,138
10 Day Avg. Volume253,334
30 Day Avg. Volume319,550
Standard Deviation0.34
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.23
Forecast
1Y Price Target
$12.38Price Target Upside645.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
PDS Biotechnology News
PremiumCompany Announcements
PDS Biotechnology Highlights Clinical Progress and Q3 Results
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPDS Biotechnology's Versamune HPV demonstrated compelling efficacy in the Phase II VERSATILE-002 trial, setting the stage for a Phase III initiation.
Regulatory AdvancementsA revised protocol has been submitted to the FDA, with clearance expected soon, which shows proactive steps toward advancing the trial.
Strategic Trial DesignThe VERSATILE-003 Phase III trial design has been streamlined to shorten the path and reduce costs, which is expected to lead to earlier interim analysis results.
Bears Say
Market ReactionPDS shares tumbled following the company's 3Q24 update, potentially driven by recent discussions around KEYNOTE-689 data.
Price Target ReductionThe price target has been trimmed from $9 to $7 due to expected dilution from anticipated cash influx and modest impact from earlier treated patients in various settings.
Study Population ConcernsThe KN-689 study is not the population that would eventually be eligible for VERSATILE-003.
---
Ownership Overview
1.52%
Insiders
5.33% Mutual Funds
0.22% Other Institutional Investors
88.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PDSB FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was $1.30 and its highest was $6.68 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
PDS Biotechnology Corporation’s market cap is $57.98M.
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is Mar 27, 2025 which is in 55 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on Nov 14, 2024. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.297 by $0.007.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate is -0.31.
How many shares outstanding does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 37,409,138 shares outstanding.
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.297. Following the earnings report the stock price went down -18.478%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Currently, no hedge funds are holding shares in PDSB
---
PDS Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.38 (645.78% Upside)
$12.38 (645.78% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 117.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.55%
12-Months-Change
Fundamentals
Return on Equity
-174.49%
Trailing 12-Months
Asset Growth
-8.28%
Trailing 12-Months
Company Description
PDS Biotechnology Corporation
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
---
PDSB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong progress in clinical trials with significant improvements in clinical outcomes and promising data from IMMUNOCERV Phase II. Despite increased R&D expenses and some delays in other development areas, the overall sentiment is positive due to robust clinical results and strong interest in ongoing trials.Read More>---
PDSB Stock 12 Month Forecast
Average Price Target
$12.38
▲(645.78% Upside)
Technical Analysis
Nektar Therapeutics
―
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Immunovant
―
Best Analysts Covering PDSB
1 Year
1 Year Success Rate
4/26 ratings generated profit
1 Year Average Return
-31.78%
reiterated a buy rating 3 months ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -31.78% per trade.
---